Doxfly-DT is a highly effective pharmaceutical formulation that combines two powerful bronchodilators: Doxofylline and Terbutaline Sulphate. This combination is specifically engineered to provide comprehensive relief for patients suffering from chronic respiratory conditions. By targeting the smooth muscles of the airways, Doxfly-DT helps in dilating the bronchial passages, making it significantly easier for patients to breathe and reducing the overall effort required for respiration during acute flare-ups.

As a leading product in the antiasthmatic and antiallergic range, Doxfly-DT is primarily indicated for the treatment and management of bronchial asthma and Chronic Obstructive Pulmonary Disease (COPD). Doxofylline, a next-generation methylxanthine derivative, offers a superior safety profile compared to traditional alternatives, while Terbutaline Sulphate acts as a fast-acting beta-agonist to open tightened airways. Together, they work synergistically to prevent shortness of breath, wheezing, and chest tightness.

The advanced formulation of Doxfly-DT ensures a steady therapeutic effect, which is crucial for long-term respiratory maintenance. It is particularly beneficial for individuals who require regular medication to keep their airways clear and prevent recurring asthma attacks. The balanced composition of these two active ingredients allows for a reduced frequency of symptoms, enabling patients to maintain an active lifestyle without the constant threat of respiratory distress or fatigue.

Manufactured by MK Healthcare, Doxfly-DT is produced in state-of-the-art facilities following strict WHO-GMP and ISO quality standards. The tablets are available in secure 10x10 Alu-Alu packaging, which preserves the integrity and potency of the medicine by protecting it from environmental moisture and light. MK Healthcare offers Doxfly-DT for PCD pharma franchise and third-party manufacturing, providing a reliable and high-demand solution for healthcare partners focused on respiratory wellness.